BioNTech SE (BNTX)
97.91
-0.89
(-0.90%)
USD |
NASDAQ |
Jun 12, 16:00
98.02
+0.11
(+0.11%)
After-Hours: 20:00
BioNTech Research and Development Expense (Quarterly): 551.24M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 551.24M |
| December 31, 2023 | 622.24M |
| September 30, 2023 | 542.11M |
| June 30, 2023 | 407.17M |
| March 31, 2023 | 358.73M |
| December 31, 2022 | 521.28M |
| September 30, 2022 | 344.32M |
| June 30, 2022 | 425.64M |
| March 31, 2022 | 320.70M |
| December 31, 2021 | 310.52M |
| September 30, 2021 | 307.03M |
| June 30, 2021 | 242.36M |
| Date | Value |
|---|---|
| March 31, 2021 | 260.52M |
| December 31, 2020 | 306.42M |
| September 30, 2020 | 266.27M |
| June 30, 2020 | 104.85M |
| March 31, 2020 | 71.84M |
| December 31, 2019 | 72.49M |
| September 30, 2019 | 56.04M |
| June 30, 2019 | 59.99M |
| March 31, 2019 | 65.02M |
| December 31, 2018 | 59.13M |
| September 30, 2018 | 38.13M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
56.04M
Minimum
Sep 2019
622.24M
Maximum
Dec 2023
307.59M
Average
308.77M
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc | 2.493B |
| Moderna Inc | 1.063B |
| GSK PLC | 1.819B |
| Cellectis SA | 22.32M |
| Adaptimmune Therapeutics PLC | 35.21M |